Home › Companies › ELDN

Eledon Pharmaceuticals

Market cap $167M 84.5M shares (10-Q, Nov 10, 2026) × $1.98 close Nov 17, 2026

Most recent annual filing: 2026-03-19

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. Tegoprubart kidney Ph3 startlate 2026Tegoprubart kidney Ph3 start, late 2026, notable
  2. LEGACY Phase 3 Ph3 start4Q 2026LEGACY Phase 3 Ph3 start, 4Q 2026, routine
  3. Eledon financing2Q 2027Eledon financing, 2Q 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (3 active programs)

Discontinued (1)

Capital (as filed)

Cash
$6.9M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$62.8M Sep 30, 2026
Operating cash flow
−$19.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$69.7M cash, runway Q2 2027 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (4)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (4 calls)

Every verdict Biotech Distilled has published on Eledon Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Eledon Pharmaceuticals (ELDN) — Scientific Deep Dive for Tegoprubart and Pipeline Products Despite compelling biology and tolerability differentiation, a missed Phase 2 primary endpoint, undisclosed Phase 3 NI margin, and unfunded trial behind a going-concern conclusion leave too many unresolved questions to open a position.
  2. Watch UPDATE: Eledon Pharmaceuticals (ELDN) - The Islet Program Grows Up Islet IND filing converts the most under-modeled asset into a company-owned registrational path, but the undisclosed NI margin, going-concern conclusion, and worsening dilution math keep the stance at Watch.
  3. Watch UPDATE: Eledon Pharmaceuticals (ELDN) - The 24-Month Curves Keep Separating A 13-point eGFR advantage at 24 months and zero BPAR past six months strengthen the mechanistic story, but the undisclosed NI margin, completer-only analysis, and unresolved going-concern keep the stance at Watch ahead of the financing.
  4. Watch UPDATE: Eledon Pharmaceuticals (ELDN) - The Phase 3 Waits on the Wallet LEGACY's Q4 start is now formally contingent on financing, cash has fallen to $69.7M with $20.7M in committed manufacturing obligations, and a $150M raise at current prices implies ~53% dilution — the raise remains the event to engage around, not ahead of.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (19)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 13, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

12 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)